01. Doctor Overview
Dr. David H. Harpole, Jr. currently holds the position of Associate Professor of Surgery and Assistant Professor of Pathology at Duke University Medical Center in Durham, North Carolina.
Research interests for Dr. Harpole focus on general thoracic surgery, advanced airway and thoracoscopic surgery, benign and malignant disease of the lung, esophagus and mediastinum; esophageal cancer, oncology, and hyperhidrosis palmaris.
Other research interests include non-small cell lung cancer, and clinical research on the development of esophageal cancer treatment protocol as well as the creation of databases, the development of risk associated models of morbidity in cancer patients that undergo thoracic surgery procedures, as well as the cost and satisfaction evaluation of thoracoscopy and open throacotomy in cancer patients. Dr. Harpole has authored or co-authored a number of scholarly publications to share his knowledge with others in the medical field.
02. Fast Facts
Doctor Fast Facts
Main Specialty: Thoracic Surgeon
Other Interests & Specialties: Mesothelioma and thymoma clinical trials, pneumonectomy, genomics of lung cancer and mesothelioma, new drug development, melanoma, thoracoscopy, esophagus cancer, squamous cell carcinoma and minimally invasive thoracic surgery.
Certifications, Awards & Accolades: American Board of Surgery Certification in Surgery, American Board of Surgery Certification in Thoracic and Cardiac Surgery, ACS Fellow, Maxwell’s Who’s Who of North America, Who’s Who in Medical Sciences Education, Cancer Doctors for Women, National Science Foundation Research Scholar, International Health Professional of the Year, CMS Stage 1 EHR
Education & Experience:
- Medical Degree from University of Virginia School of Medicine
- Residency for General Surgery at Duke University Medical Center
- Fellowship for Thoracic Surgery at Duke University Medical Center
- Fellowship for Thoracic Oncology at Dana Farber Cancer Institute, Harvard Medical School
Did You Know?
Long-term Survival After Surgery Compared With Concurrent Chemoradiation for Node-negative Small Cell Lung Cancer. The Annals of Surgery. December 2018;268(6):1105-1112. doi: 10.1097/SLA.0000000000002287
Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. Journal of Thoracic Oncology. November 2018;13(11):1655-1667. doi: 10.1016/j.jtho.2018.08.2036
Impact of Age on Long-Term Outcomes of Surgery for Malignant Pleural Mesothelioma. Clinical Lung Cancer. September 2016;419-426. doi: 10.1016/j.cllc.2016.03.002
Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. The Journal of Surgical Research. June 2015;196(1):23-32. doi: 10.1016/j.jss.2015.01.043